- CILTEP can improve cognition in healthy volunteers, specifically memory - The effects of CILTEP will be discernable in the ERP components measured: the P50, P300, N400, and P600 amplitudes are expected to be enlarged by CILTEP
ID
Bron
Verkorte titel
Aandoening
Long-term memory
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
To establish the effects of CILTEP on cognition, especially memory. The main cognitive tests that will be used are the verbal learning task (VLT), in which participants need to memorize words that are presented on a screen, and the spatial pattern separation test, using photographs to assess episodic memory.
Achtergrond van het onderzoek
N/A
Doel van het onderzoek
- CILTEP can improve cognition in healthy volunteers, specifically memory
- The effects of CILTEP will be discernable in the ERP components measured: the P50, P300, N400, and P600 amplitudes are expected to be enlarged by CILTEP
Onderzoeksopzet
N/A
Onderzoeksproduct en/of interventie
Volunteers will be tested on 2 separate days and will be administered either CILTEP or a placebo. Before inclusion, they will undergo a memory and a medical screening The order of treatment will be randomized.
Publiek
Dept. of Neuropsychology and Psychopharmacology
PO Box 616
Anke Sambeth
Maastricht 6200 MD
The Netherlands
0031-(0)43-3881757
anke.sambeth@psychology.unimaas.nl
Wetenschappelijk
Dept. of Neuropsychology and Psychopharmacology
PO Box 616
Anke Sambeth
Maastricht 6200 MD
The Netherlands
0031-(0)43-3881757
anke.sambeth@psychology.unimaas.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Male or female;
2. 30 to 40 or 60 to 75 years of age;
3. healthy (i.e. absence of all exclusion criteria);
4. body mass index between 18.5 and 30;
5. Verbal Learning Test screening score within the -1 and +1 standard deviation;
6. willingness to sign an informed consent.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. history of cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal, haematological, or psychiatric ilness or a first-degree relative with a psychiatric disorder or a history with a psychiatric disorder;
2. excessive drinking (> 20 glasses of alcohol containing beverages a week);
3. pregnancy or lactation;
4. use of use of psychoactive medication or centrally acting beta blockers;
5. use of recreational drugs from 2 weeks before the experiment until the end of the study;
6. systolic blood pressure above 160 mmHg;
7. phenylketonuria;
8. any sensory or motor deficits which could reasonably be expected to affect test performance;
9. use of steroids or Sudafed (pseudoephedrine)
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL6001 |
| NTR-old | NTR6400 |
| CCMO | NL60999.068.17 |
| OMON | NL-OMON47611 |